Oxford Biomedica Solutions
Hung-Lun Hsu is a Scientist II currently employed at Voyager Therapeutics, Inc. since April 2024, with prior experience at Frontera Therapeutics and Oxford Biomedica Solutions, focusing on upstream and downstream process development for AAV production. At Oxford Biomedica, responsibilities included performing small-scale and bioreactor AAV production, conducting next-generation sequencing and bioinformatics for plasmid quality control, and enhancing AAV titer through construct design. Previously, at Homology Medicines, Inc., Hung-Lun Hsu contributed to AAV production and virology studies. A postdoctoral associate at the University of Massachusetts Medical School, research involved AAV-based gene therapy and the discovery of capsid variants for improved transduction efficiency. Educational qualifications include a PhD and a Master of Engineering in Chemical Engineering from Cornell University, and a Bachelor of Science from National Taiwan University.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.